Analysts Conflictied on These Healthcare Names: Regeneron (NASDAQ: REGN), Paratek Pharmaceuticals (NASDAQ: PRTK) and Alere Inc. (NYSE: ALR)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (NASDAQ: REGN), Paratek Pharmaceuticals (NASDAQ: PRTK) and Alere Inc. (NYSE: ALR).

Regeneron (NASDAQ: REGN)

Cowen & Co. analyst Phil Nadeau reiterated a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $430. The company’s shares opened today at $325.62, close to its 52-week low of $325.35.

Nadeau wrote:

“REGN a solid Q3:16 with U.S.”

According to TipRanks.com, Nadeau is ranked 0 out of 5 stars with an average return of -5.4% and a 32.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $526, representing a 61.5% upside.

In a report issued on October 28, Piper Jaffray also maintained a Hold rating on the stock with a $447 price target.
Paratek Pharmaceuticals (NASDAQ: PRTK)

In a report released today, Ed Arce from H.C. Wainwright reiterated a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK). The company’s shares opened today at $10.60, close to its 52-week low of $9.80.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 11.1% and a 25.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics, Inc., and Sucampo Pharmaceuticals.

Paratek Pharmaceuticals has an analyst consensus of Strong Buy.

Alere Inc. (NYSE: ALR)

Goldman Sachs analyst Isaac Ro maintained a Hold rating on Alere Inc. (NYSE: ALR) today and set a price target of $42. The company’s shares opened today at $42.86.

According to TipRanks.com, Ro is a 1-star analyst with an average return of -1.6% and a 58.7% success rate. Ro covers the Healthcare sector, focusing on stocks such as Quest Diagnostics Inc., Foundation Medicine, and Laboratory Corp.

Alere Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $52.